Is the emerging early stage myeloma landscape as bleak as Titan in Clydebank?

For years we have seen much of the therapeutic research in multiple myeloma concentrated on three main categories:

  • Proteasome inhibitors
  • IMiDs
  • Anti-CD38 antibodies

Then came a raft of anti- BCMA and GPRC5D targeted approaches in various forms, but what else should we be looking out for?

It turns out there’s quite a few contenders of interest – we cover some of them in our latest look at early stage compounds to watch out for…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by